Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2025
Reporting Period: Event date of February 25, 2025
Context: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Global Select Market under the symbol ORIC. This filing reports updates regarding the Company's operating plan and anticipated data release timing.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification of operational updates rather than a financial statement.
Material Changes
Item 8.01 Other Events: On February 25, 2025, the Company issued a press release (attached as Exhibit 99.1) announcing updates to its operating plan and the anticipated timing of data releases. No quantitative financial changes are detailed in the body of this report.
Guidance, Outlook, and Risks
Management Commentary: The Company has updated its operating plan and data release schedule. Specific details regarding the nature of these updates are contained in the attached press release (Exhibit 99.1) and are not explicitly summarized in the 8-K text.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the operational updates referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 25, 2025) for specific details on the revised operating plan.
- Verify the new anticipated dates for clinical data releases mentioned in the press release.
- Assess the impact of the operating plan changes on the Company's cash runway and future capital requirements.
- Confirm if the changes in data release timing affect the Company's regulatory milestones or partnership obligations.